Reliance Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Reliance Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $42.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Reliance Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $42.3M Trade | TransData Nexus

Reliance Life Sciences Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $42.3M Total Trade · DGFT Verified

Reliance Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $42.3M across 14 products in 4 therapeutic categories. Based on 1,161 verified export shipments from Indian Customs (DGFT) records, Reliance Life Sciences Private Limited is the #1 Indian exporter in 2 products including Immunoglobulin, Adalimumab. Top exports include Immunoglobulin ($15.2M), Lenalidomide ($8.3M), Rituximab ($4.1M).

Reliance Life Sciences Private Limited — Export Portfolio & Destination Treemap

Reliance Life Sciences Private Limited pharmaceutical export portfolio — 14 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Reliance Life Sciences Private Limited? — Company Overview & Market Position

Reliance Life Sciences Private Limited, established on January 30, 2001, is a prominent Indian pharmaceutical exporter headquartered in Navi Mumbai, Maharashtra. The company operates under the Corporate Identification Number (CIN) U24239MH2001PTC130654 and is classified as a private limited company. As of the latest available data, Reliance Life Sciences has an authorized capital of ₹126.01 crore and a paid-up capital of ₹96.01 crore. The company employs approximately 1,543 professionals, reflecting its substantial workforce dedicated to various facets of the pharmaceutical industry.

Reliance Life Sciences is a subsidiary of Reliance Industries Limited, a conglomerate with diversified interests across sectors such as petrochemicals, refining, and telecommunications. This affiliation provides Reliance Life Sciences with robust financial backing and access to a vast network, facilitating its operations in the pharmaceutical sector. The company's primary focus encompasses bio-therapeutics, pharmaceuticals, clinical research services, regenerative medicine, and molecular medicine. Notably, Reliance Life Sciences has launched five of the world's first biosimilars and holds the distinction of being the first integrated manufacturer of plasma proteins in South Asia.

What Does Reliance Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin

Product Portfolio — Top 14 by Export Value

Reliance Life Sciences Private Limited exports 14 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$15.2M	303	7.9%	1
2	Lenalidomide	Advanced Oncology	$8.3M	281	0.9%	5
3	Rituximab	Advanced Oncology	$4.1M	102	21.4%	2
4	Trastuzumab	Advanced Oncology	$3.8M	75	4.9%	4
5	Kit	Medical Devices & Diagnostics	$2.7M	54	0.6%	3
6	Bevacizumab	Advanced Oncology	$2.1M	73	4.5%	4
7	Pemetrexed	Advanced Oncology	$2.0M	52	6.9%	5
8	Temozolomide	Advanced Oncology	$1.7M	100	7.1%	4
9	Capecitabine	Advanced Oncology	$1.4M	68	1.5%	9
10	Etanercept	Biologics & Immunotherapy	$450.0K	9	0.7%	3
11	Adalimumab	Biologics & Immunotherapy	$338.1K	20	28.3%	1
12	Sunitinib	Advanced Oncology	$204.8K	6	0.3%	7
13	Bortezomib	Advanced Oncology	$125.3K	11	0.6%	14
14	Erlotinib	Advanced Oncology	$102.9K	7	3.8%	6

Reliance Life Sciences Private Limited exports 14 pharmaceutical products across 4 therapeutic categories with a total export value of $42.3M. The company is the #1 Indian exporter in 2 products: Immunoglobulin, Adalimumab. The top category is Advanced Oncology (56.0% of portfolio), followed by Other (35.8%), indicating a concentrated portfolio with the top 5 products accounting for 80.2% of total export value.

Reliance Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Reliance Life Sciences operates state-of-the-art manufacturing facilities, with its flagship plant located at the Dhirubhai Ambani Life Sciences Centre (DALC) in Navi Mumbai, Maharashtra. This facility is recognized for its world-class manufacturing capabilities and has received approvals from both Indian and international regulatory agencies. The company has also expanded its manufacturing footprint with the establishment of Reliance Life Sciences Nashik Private Limited in February 2022. This facility is situated in Nashik, Maharashtra, and is part of the company's strategic expansion to enhance its production capacity and meet the growing demand for its pharmaceutical products.

3Key Leadership

The leadership team at Reliance Life Sciences comprises seasoned professionals with extensive experience in the pharmaceutical industry. As of the latest available data, the board of directors includes:

Venkata Ramana – Whole-Time Director, appointed on January 10, 2022.
Laxmidas Vallabhdas Merchant – Director, serving since June 1, 2007.
Shailaja Gada Saxena – Whole-Time Director, appointed on September 30, 2022.
Ramaprasad Jayaraman – Whole-Time Director, serving since July 1, 2016.
Vinay Arvind Ranade – Whole-Time Director, serving since July 1, 2016.

These leaders bring a wealth of expertise to the company, steering its strategic direction and operational excellence in the competitive pharmaceutical landscape.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Reliance Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Reliance Life Sciences has made significant strides in establishing a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's commitment to quality and compliance is evident through its adherence to stringent regulatory standards. While specific details regarding regulatory filings and approvals in these markets are not publicly disclosed, the company's robust manufacturing facilities and international collaborations suggest a proactive approach to meeting global regulatory requirements. Reliance Life Sciences' focus on biosimilars and complex generics positions it favorably to navigate the regulatory landscapes of these markets, where demand for such products is on the rise.

2Emerging Markets

In addition to its presence in regulated markets, Reliance Life Sciences has strategically expanded its footprint into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's commitment to global health is underscored by its efforts to obtain World Health Organization (WHO) prequalification for its products, facilitating access to these markets. WHO prequalification is a critical step for pharmaceutical companies aiming to supply medicines to international organizations and governments, ensuring that products meet international standards of quality, safety, and efficacy. Reliance Life Sciences' focus on biosimilars and essential medicines aligns with the healthcare needs of these regions, positioning the company as a key player in improving access to affordable and high-quality pharmaceuticals.

Reliance Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Reliance Life Sciences has demonstrated a commitment to meeting international regulatory standards, including those set by the U.S. Food and Drug Administration (FDA). While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's adherence to stringent quality management systems and its focus on biosimilars and complex generics suggest a proactive approach to FDA compliance. The FDA's rigorous standards for drug approval and manufacturing practices necessitate that companies like Reliance Life Sciences maintain high-quality production processes and comprehensive documentation. The company's established manufacturing facilities, such as the Dhirubhai Ambani Life Sciences Centre, are indicative of its capability to meet international regulatory requirements, including those of the FDA.

2WHO & EU GMP

Reliance Life Sciences has achieved significant milestones in obtaining certifications from the World Health Organization (WHO) and the European Union's Good Manufacturing Practice (EU GMP). The company's manufacturing facilities, including the Dhirubhai Ambani Life Sciences Centre, have received approvals from Indian and international regulatory agencies, reflecting compliance with WHO and EU GMP standards. These certifications are crucial for ensuring that pharmaceutical products meet international standards of quality, safety, and efficacy. Reliance Life Sciences' commitment to maintaining high manufacturing standards positions it favorably in the global pharmaceutical market, enabling access to a broader range of markets and enhancing its reputation as a reliable supplier of quality medicines.

Reliance Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Reliance Life Sciences operates in a competitive landscape characterized by both domestic and international pharmaceutical companies. In the biosimilars segment, the company faces competition from global players such as Biocon Limited and Dr. Reddy's Laboratories, which have established biosimilar portfolios. However, Reliance Life Sciences distinguishes itself by launching five of the world's first biosimilars and holding the largest number of biosimilars in the Indian market. This innovative approach positions the company as a leader in the biosimilars space, offering a competitive edge in terms of product differentiation and market presence. Additionally, the company's focus on complex generics and plasma proteins further diversifies its product offerings, enabling it to cater to a broader patient base and address unmet medical needs.

2Key Differentiators

Reliance Life Sciences' key differentiators include its strong research and development capabilities, evidenced by the launch of five of the world's first biosimilars. The company's integrated approach to manufacturing, encompassing both biosimilars and plasma proteins, allows for greater control over product quality and supply chain efficiency. Additionally, Reliance Life Sciences' commitment to

TransData Nexus Research · DGFT export records, industry analysis

Frequently Asked Questions — Reliance Life Sciences Private Limited

How many pharmaceutical products does Reliance Life Sciences Private Limited export from India?

Reliance Life Sciences Private Limited exports 14 pharmaceutical products across 4 therapeutic categories. The top exports are Immunoglobulin ($15.2M), Lenalidomide ($8.3M), Rituximab ($4.1M), Trastuzumab ($3.8M), Kit ($2.7M). Total export value is $42.3M.

What is Reliance Life Sciences Private Limited's total pharmaceutical export value?

Reliance Life Sciences Private Limited's total pharmaceutical export value is $42.3M, based on 1,161 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Reliance Life Sciences Private Limited the #1 Indian exporter?

Reliance Life Sciences Private Limited is the #1 Indian exporter in 2 products: Immunoglobulin (7.9% market share), Adalimumab (28.3% market share).

What therapeutic categories does Reliance Life Sciences Private Limited cover?

Reliance Life Sciences Private Limited exports across 4 therapeutic categories. The largest are Advanced Oncology (56.0%, 10 products), Other (35.8%, 1 products), Medical Devices & Diagnostics (6.4%, 1 products).

Get Full Reliance Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.